AB0499 Post-discontinuation treatment patterns for tumor necrosis factor-blockers in rheumatoid arthritis patients in the US

Background Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are the 3 most frequently prescribed tumor necrosis factor (TNF)-blocker therapies that are approved by the US Food & Drug Administration for treatment of moderate to severe rheumatoid arthritis (RA). Clinical guidelines and pub...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.666
Hauptverfasser:	Schabert, V.F., Fox, K.M., Watson, C., Yeaw, J., Goodman, S., Gandra, S.R.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!